Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NEO100-02
- Development stage
- Phase 2
- Lead developer
- NEONC Technologies
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Inhalation Devices → Device-based Delivery → Drug Delivery Systems, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Intranasal
01
Overview
NEO100-02 is a proprietary, highly purified intranasal formulation of perillyl alcohol (POH), developed by NeOnc Technologies for the treatment of high-grade meningioma and other central nervous system (CNS) tumors. Perillyl alcohol is a naturally occurring monoterpene found in the essential oils of certain plants, such as citrus. The drug leverages NeOnc’s patented NEO™ technology platform to enable non-invasive delivery directly to the brain via the nasal route, bypassing the blood-brain barrier through olfactory and trigeminal nerve pathways. This approach aims to improve drug delivery efficacy for CNS malignancies while reducing systemic toxicity and treatment burden compared to traditional chemotherapy or surgery. The mechanism of action is believed to involve direct cytotoxic effects on tumor cells and modulation of tumor microenvironment, though precise molecular targets are not fully elucidated[1][3][5][6].
- Brand names
- NEO100-02NEO-100-02NEO 100-02
- Other names
- NEO100NEO-100NEO 100perillyl alcohol intranasal formulation
02
Targets
ATP1A1 (Sodium/potassium-transporting ATPase subunit alpha-1)FTase (Protein Farnesyltransferase)TERT (Telomerase)
Beyond the preview
Go deeper on NEO100-02.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NEO100-02.